Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Lord

Showing results (101-110 of 223) with videos related to

Pageof 23
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 14, 2021
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)Susana Banerjee, James Stewart, Nuria Porta, et al.
Plos One|May 2, 2013
A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicityStephen J Pettitt, Farah L Rehman, Ilirjana Bajrami, et al.
Diabetes|December 28, 2002
The derivation of highly germline-competent embryonic stem cells containing NOD-derived genomeFrances A Brook, Edward P Evans, Christopher J Lord, et al.
British Journal of Cancer|May 29, 2025
Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinomaKatharine J Herbert, Rosie Upstill-Goddard, Stephan B Dreyer, et al.
The Journal of Pathology|July 8, 2011
Functional characterization of EMSY gene amplification in human cancersPaul M Wilkerson, Konstantin J Dedes, Daniel Wetterskog, et al.
The Journal of Biological Chemistry|June 9, 2016
Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell LymphomaDaniel Beck, Jenny Zobel, Ruth Barber, et al.
Breast Cancer Research : BCR|December 11, 2007
Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancersMatthew J Smalley, Marjan Iravani, Maria Leao, et al.
The Journal of Pathology|August 12, 2016
Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 modelSarah L Maguire, Barrie Peck, Patty T Wai, et al.
Stem Cells (Dayton, Ohio)|June 8, 2012
Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancersAnna L Stratford, Kristen Reipas, Kaiji Hu, et al.
Plos One|March 10, 2012
A modified method for whole exome resequencing from minimal amounts of starting DNAIwanka Kozarewa, Juan Manuel Rosa-Rosa, Christopher P Wardell, et al.
Pageof 23

Showing results (101-110 of 223) with videos related to

Sort By:
Pageof 23
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 14, 2021
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)Susana Banerjee, James Stewart, Nuria Porta, et al.
Plos One|May 2, 2013
A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicityStephen J Pettitt, Farah L Rehman, Ilirjana Bajrami, et al.
Diabetes|December 28, 2002
The derivation of highly germline-competent embryonic stem cells containing NOD-derived genomeFrances A Brook, Edward P Evans, Christopher J Lord, et al.
British Journal of Cancer|May 29, 2025
Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinomaKatharine J Herbert, Rosie Upstill-Goddard, Stephan B Dreyer, et al.
The Journal of Pathology|July 8, 2011
Functional characterization of EMSY gene amplification in human cancersPaul M Wilkerson, Konstantin J Dedes, Daniel Wetterskog, et al.
The Journal of Biological Chemistry|June 9, 2016
Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell LymphomaDaniel Beck, Jenny Zobel, Ruth Barber, et al.
Breast Cancer Research : BCR|December 11, 2007
Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancersMatthew J Smalley, Marjan Iravani, Maria Leao, et al.
The Journal of Pathology|August 12, 2016
Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 modelSarah L Maguire, Barrie Peck, Patty T Wai, et al.
Stem Cells (Dayton, Ohio)|June 8, 2012
Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancersAnna L Stratford, Kristen Reipas, Kaiji Hu, et al.
Plos One|March 10, 2012
A modified method for whole exome resequencing from minimal amounts of starting DNAIwanka Kozarewa, Juan Manuel Rosa-Rosa, Christopher P Wardell, et al.
Pageof 23